17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Leukemia Research
Jennifer M Napper, Vincent E Sollars

Abstract

The goal of this study was to ascertain the specific effects of 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) treatment in human acute myelogenous leukemia (AML). Four human leukemia cell lines were treated with varying doses of 17-AAG followed by analysis of toxicity, apoptosis, proliferation, and cell cycle. Cell cycle analysis revealed that the cells accumulate in G2/M phase within 96 h of treatment, although the effect was not equivalent among the cell lines. p21, p53 expression and MDR1 activity were among the possible mechanisms uncovered for the differing responses. Exploiting these differences may allow for more effective combinatory treatments in patients with AML.

References

May 1, 1993·Nature Genetics·D DittmerA J Levine
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·M V BlagosklonnyL Neckers
Jul 1, 1997·Leukemia·J Pétriz, J García-López
Apr 3, 2002·Trends in Molecular Medicine·Len Neckers
Sep 28, 2004·Journal of Cellular Biochemistry·Ella Kim, Wolfgang Deppert
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean L GremRichard H Wilson
Nov 12, 2005·Journal of Cancer Research and Clinical Oncology·Megumi SenjuEisaburo Sueoka
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nina AnensenBjorn Tore Gjertsen
Sep 13, 2006·Molecular and Cellular Biology·Joogyung HyunDirk Bohmann
Apr 4, 2008·Cell Stress & Chaperones·Pascale FlandrinLydia Campos
Oct 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Junichi OkamotoDavid M Jablons
May 15, 2009·Nature Reviews. Cancer·Tarek Abbas, Anindya Dutta
Jul 16, 2009·Current Molecular Medicine·Saad Z UsmaniZihai Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.